title: The Changing Paradigm of Atopic Dermatitis Therapy.
abstract: The pathophysiology of atopic dermatitis (AD) is complex, and future treatment options will likely be incorporated in a multimodal approach to management. The new, directed therapies that have been developed will likely be used in conjunction with concomitant continuous or intermittent use of standard therapies; the goal is to optimize therapeutic outcomes while minimizing adverse impacts on safety and cost. Current data regarding disease course and expression throughout life suggest that treatment strategies also will need to be adjusted as a patient grows. Research also indicates that interventions begun in infancy-such as the use of emollients-may mitigate or prevent AD signs and symptoms in children at high risk for the disease. Semin Cutan Med Surg 35(supp5):S97-S99.
authors.affiliation: Professor of Dermatology and Pediatrics University of California San Diego School of Medicine Fellowship Program Director Pediatric and Adolescent Dermatology Rady Children's Hospital San Diego, California.
authors.forename: Sheila F
authors.initials: SF
authors.lastname: Friedlander
authors.affiliation: Professor of Dermatology Director of Clinical Studies Oregon Health and Science University Department of Dermatology Portland, Oregon.
authors.forename: Eric L
authors.initials: EL
authors.lastname: Simpson
authors.affiliation: Professor of Dermatology Trinity College Dublin Attending Dermatologist Our Lady's Children's Hospital Crumlin St. James's Hospital Dublin, Ireland.
authors.forename: Alan D
authors.initials: AD
authors.lastname: Irvine
authors.affiliation: Professor of Dermatology and Pediatrics Chief, Pediatric and Adolescent Dermatology University of California San Diego School of Medicine Rady Children's Hospital San Diego, California.
authors.forename: Lawrence F
authors.initials: LF
authors.lastname: Eichenfield
mesh_terms: D065095:Calcineurin Inhibitors / Q000627:therapeutic use; D002648:Child; D003876:Dermatitis, Atopic / Q000188:drug therapy*; D017277:Drug Approval; D055808:Drug Discovery; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D065095:Calcineurin Inhibitors; D007155:Immunologic Factors
keywords: Atopic dermatitis; petrolatum; pimecrolimus; tacrolimus; topical calcineurin inhibitors; topical immunomodulators